Invention Grant
- Patent Title: Stabilized formulations containing anti-PCSK9 antibodies
-
Application No.: US16384298Application Date: 2019-04-15
-
Publication No.: US10752701B2Publication Date: 2020-08-25
- Inventor: Scott M. Walsh , Daniel B. Dix
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: US NY Tarrytown
- Agency: Lathrop GPM LLP
- Agent James H. Velema, Esq.
- Main IPC: C07K16/40
- IPC: C07K16/40 ; A61K39/395 ; A61K47/22 ; A61K47/26 ; A61M5/32 ; A61M5/315
Abstract:
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Public/Granted literature
- US20190284301A1 STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES Public/Granted day:2019-09-19
Information query
